A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
Clinical Trials Related to Bortezomib
Related studies linked through entity extraction aliases.
Combination Chemotherapy With or Without Bortezomib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Bortezomib in Treating Patients With Malignant Pleural Mesothelioma
- Status
- COMPLETED
- Phase
- PHASE2
Velcade (Bortezomib - PS341) in the Treatment of Patients Over 18 Years With Ph+ Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
Bortezomib and High-dose Melphalan at Myeloma Relapse
- Status
- UNKNOWN
- Phase
- PHASE2
Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone
- Status
- COMPLETED
- Phase
- PHASE3
Bortezomib (Velcade) Post Allogenic Peripheral Blood Stem Cell Transplantation for Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma
- Status
- WITHDRAWN
- Phase
- PHASE1
Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (AMBER)
- Status
- COMPLETED
- Phase
- PHASE2
A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE2
Bortezomib and Cisplatin as First-Line Therapy in Treating Patients With Malignant Mesothelioma
- Status
- COMPLETED
- Phase
- PHASE2
Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis
- Status
- COMPLETED
- Phase
- PHASE2
Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE2